Daily Filing Digest — 16 Sep 2026

A hospital chain just found a way to add 400+ beds without owning an inch of the real estate. Fortis Healthcare signed a 29-year exclusive services agreement to run a new Delhi hospital that someone else will build and own — the kind of asset-light expansion that's easy to describe and rare to actually see filed. Elsewhere: a Mumbai jewellery house's founding family is exiting entirely, and an MSME lender landed its third development-finance backer in three years.

The one to read first

Fortis Healthcare's wholly owned subsidiary signed definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital (SLJ Society) to provide healthcare services to a new 400+ bedded super specialty hospital in Ashok Vihar, New Delhi. SLJ Society will own, build and operate the hospital itself on ~3.1 acres; Fortis's subsidiary gets long-term exclusive rights to provide inpatient services and specialized equipment in exchange for a service fee, under a Healthcare Services Agreement with a committed term of 29 years. Fortis is also lending SLJ Society up to ₹567 crore in phased tranches over the next 3-4 years to fund construction — secured, interest-bearing, and disbursed against construction progress. Per the company's own press release, this extends Fortis's Delhi-NCR footprint to more than 3,400 beds without adding a single owned facility to its balance sheet.

Capital structure and ownership

Tribhovandas Bhimji Zaveri (TBZ) — GRT Jewellers filed the draft letter of offer for its mandatory open offer following its earlier deal to acquire control of the Mumbai jewellery retailer. The open offer is priced at ₹249.61 per share for up to 1,72,70,845 shares (25.88% of voting capital) — roughly ₹431 crore if fully subscribed, on top of the earlier promoter-stake purchase. Whether the "Zaveri Bazar" brand identity survives a change of control to a South India-based acquirer is the real question the filing itself can't answer.

UGRO Capital raised ₹380 crore from FMO, the Dutch development finance institution — its third investment in the MSME lender in three years, deepening a repeat funding relationship rather than a one-off capital raise.

Pricing power, in a company's own words

Piramal Finance's Q1 FY27 analyst presentation makes an explicit peer-relative claim: the company says it's "one of the fastest among retail NBFCs" to scale AUM from ₹20,000 crore to ₹90,000 crore, while cutting retail opex-to-AUM by roughly 300 basis points over the same 13 quarters. Retail AUM grew 32% year-on-year to ₹91,249 crore, PAT rose 67% to ₹461 crore, and asset quality actually improved (GNPA down to 2.4% from 2.8%) even as the book scaled. A full breakdown of what this filing demonstrates about cost-advantage-at-scale is up as a separate piece — see Piramal Finance Says It's Growing Faster Than Peers While Its Costs Fall once published.

Also filed, thinner on detail

Exide Industries entered a strategic cooperation with Germany's ExCom for industrial batteries across the EEA, terms undisclosed. MobiKwik flagged that NPCI's new merchant discount rate on UPI payments above ₹2,000 will affect the business, but by its own account hasn't yet quantified the magnitude. Kalpataru Projects received prospectus approval for its Swedish subsidiary LMG's IPO. Aditya Birla Real Estate's CEO cessation filing confirmed the previously announced sale of Century Pulp & Paper to ITC has closed.

A large share of today's 126-filing queue was procedural: SAST Regulation 29(1)/29(2)/31 shareholding-disclosure filings (IIRM Holdings, Cupid, Sacheta Metals, Steel Strips Wheels, Axiscades, and a dozen others) that named a stake movement without disclosing size or price in the filing summary; a cluster of routine AGM/EGM scrutiniser's-report and voting-result filings (Sinclair Hotels, Sigachi Industries, Amanta Healthcare, Zuari Agro Chemicals); and standard KMP/director appointment-or-resignation notices with no further detail (Gulf Oil Lubricants, PSP Projects, Uttam Sugar Mills, Vaibhav Global, and several more).

Educational research, not investment advice. Figures above are drawn from primary filings and independently verified against the source PDF in every case where a specific number is cited. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.